HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Atezolizumab plus bevacizumab is the first-line treatment for patients with advanced
hepatocellular carcinoma. However, the prognosis for high-risk hepatocellular carcinoma is
still poor, with a median overall survival of 7.6 months. Hepatic arterial infusion
chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin is effective in large
hepatocellular carcinoma or hepatocellular carcinoma with major portal vein tumor thrombus.
Our previous showed that hepatic arterial infusion chemotherapy plus lenvatinib and
toripalimab (programmed cell death protein-1 antibody) had a powerful anti-tumor effect for
high-risk hepatocellular carcinoma, with a median overall survival of 18 months. Thus, the
purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion
chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus atezolizumab plus bevacizumab
for patients with high-risk hepatocellular carcinoma.